Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma

Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric antigen receptor (CAR) T cells approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We performed a retrospective study to evaluate safety and efficacy of axi-cel and tisa-cel outside the sett...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwon, Mi, Iacoboni, Gloria, Reguera, Juan Luis, Corral, Lucía López, Morales, Rafael Hernani, Ortiz-Maldonado, Valentín, Guerreiro, Manuel, Caballero, Ana Carolina, Domínguez, María Luisa Guerra, Pina, Jose Maria Sanchez, Mussetti, Alberto, Sancho, Juan Manuel, Bastos-Oreiro, Mariana, Catala, Eva, Delgado, Javier, Henriquez, Hugo Luzardo, Sanz, Jaime, Calbacho, María, Bailén, Rebeca, Carpio, Cecilia, Ribera, Jose Maria, Sureda, Anna, Briones, Javier, Hernandez-Boluda, Juan Carlos, Cebrián, Nuria Martínez, Martin, Jose Luis Diez, Martín, Alejandro, Barba, Pere
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Article - Cell Therapy & Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827173/
https://www.ncbi.nlm.nih.gov/pubmed/35770532
http://dx.doi.org/10.3324/haematol.2022.280805

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827173/
https://www.ncbi.nlm.nih.gov/pubmed/35770532
http://dx.doi.org/10.3324/haematol.2022.280805

Ejemplares similares